Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer

Abstract

Background: Amivantamab was approved on May 21st, 2021, by United States food and drug administration with the brand name Rybervant, used particularly for adult patients with exon20 insertion of epithelial growth factor receptor with locally advanced metastatic non-small cell lung cancer. Objective: In this review, we explain the non-small cell lung cancer and molecular distinctions between non-small cell lung cancer and small cell lung cancer. We also conclude numerous components of non-small cell lung cancer, which include signs and symptoms of Amivantamab in inhibiting the cancer cell growth, various clinical trials on Amivantamab, adverse effects, and the contraindications of Amivantamab. Methods: A comprehensive literature search was conducted in the relevant databases like ScienceDirect, PubMed, ResearchGate, and Google Scholar to identify studies. Conclusion: Amivantamab is a new bispecific antibody that targets non-small cell lung cancer through two different pathways, i.e., by binding to epithelial growth factor receptor and mesenchymal epithelial transition factor. Amivantamab gets tightly bound to Fcγ3R, and thus, mediates the macrophage and NK-cell for the killing of cancer cells. Biological treatment of Amivantamab shows effectiveness against the epithelial growth factor receptor Exon20 insertions according to the preclinical data of the animal model.